{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:56Z","timestamp":1787067716036,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.beha.2019.101130","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T12:19:03Z","timestamp":1575375543000},"page":"101130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes \u2013 Advances in treatment"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-2619","authenticated-orcid":false,"given":"Kristen B.","family":"McCullough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.beha.2019.101130_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2019.101130_bib2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2019.101130_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.101130_bib4","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2019.101130_bib5","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1038\/bcj.2017.41","article-title":"Validation of response assessment according to international consortium for MDS\/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents","volume":"7","author":"Duchmann","year":"2017","journal-title":"Blood Canc J"},{"issue":"7","key":"10.1016\/j.beha.2019.101130_bib6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","article-title":"Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients","volume":"94","author":"Coston","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.beha.2019.101130_bib7","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.101130_bib8","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2019.101130_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ejh.12679","article-title":"Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia","volume":"97","author":"Xicoy","year":"2016","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2019.101130_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies","volume":"89","author":"Hellstrom-Lindberg","year":"1995","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2019.101130_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00277-008-0450-7","article-title":"Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis","volume":"87","author":"Moyo","year":"2008","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.beha.2019.101130_bib12","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2019.101130_bib13","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2019.101130_bib14","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.beha.2019.101130_bib15","article-title":"Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management","author":"Patnaik","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2019.101130_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13576","volume":"171","author":"Symeonidis","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2019.101130_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2019.101130_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2018-99-110805","volume":"132","author":"Fenaux","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2019.101130_bib19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2019-123064","volume":"134","author":"Fenaux","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2019.101130_bib20","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2019-123048","volume":"134","author":"Garcia-Manero","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.101130_bib21","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2019.101130_bib22","author":"Reblozyl (luspatercept-aamt)","year":"2019"},{"issue":"25","key":"10.1016\/j.beha.2019.101130_bib23","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2019.101130_bib24","first-page":"4243","article-title":"A phase 1 study of lenzilumab, a humaneered recombinant anti\u2013human granulocyte-macrophage colony- stimulating factor (anti-hGM-CSF) antibody, for chronic myelomonocytic leukemia (CMML)","volume":"134","author":"Patnaik","year":"2019","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.beha.2019.101130_bib25","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.clml.2016.02.009","article-title":"Eltrombopag use in patients with chronic myelomonocytic leukemia (CMML): a cautionary tale","volume":"16","author":"Ramadan","year":"2016","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2019.101130_bib26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.beha.2019.101130_bib27","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(19)30029-8","article-title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1\/2 trial","volume":"6","author":"Garcia-Manero","year":"2019","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2019.101130_bib28","first-page":"3846","article-title":"Landmark response and survival analyses from 102 MDS and CMML patients treated with guadecitabine in a phase 2 study showing that maximum response and survival is best achieved with adequate treatment duration","volume":"134","author":"Savona","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2019.101130_bib29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0006-2952(65)90175-9","article-title":"Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity","volume":"14","author":"Camiener","year":"1965","journal-title":"Biochem Pharmacol"},{"issue":"18","key":"10.1016\/j.beha.2019.101130_bib30","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2019.101130_bib31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jcph.251","article-title":"Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies","volume":"54","author":"Laille","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.beha.2019.101130_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2015.265","article-title":"Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Garcia-Manero","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2019.101130_bib33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ajh.25216","article-title":"Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies","volume":"93","author":"Savona","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2019.101130_bib34","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","article-title":"An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study","volume":"6","author":"Savona","year":"2019","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2019.101130_bib35","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2019-122980","article-title":"Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine\/decitabine) compared to IV decitabine","volume":"134","author":"Garcia-Manero","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2019.101130_bib36","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML)","volume":"22","author":"Padron","year":"2016","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2019.101130_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.beha.2019.101130_bib38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2019.101130_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2019-123854","article-title":"Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)","volume":"134","author":"Steensma","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2019.101130_bib40","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","article-title":"Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia","volume":"33","author":"Lucas","year":"2019","journal-title":"Leukemia"},{"issue":"15_suppl","key":"10.1016\/j.beha.2019.101130_bib41","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1200\/JCO.2019.37.15_suppl.7059","article-title":"Results from ongoing phase 1\/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed\/refractory chronic myelomonocytic leukemia (CMML)","volume":"37","author":"Patnaik","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.101130_bib42","author":"Elzonris (tagraxofusp-erzs)","year":"2018"},{"issue":"17","key":"10.1016\/j.beha.2019.101130_bib43","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2019.101130_bib44","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101130_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.blre.2018.07.004","article-title":"Current and evolving understanding of atypical chronic myeloid leukemia","volume":"33","author":"Schwartz","year":"2019","journal-title":"Blood Rev"},{"issue":"19","key":"10.1016\/j.beha.2019.101130_bib46","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2019.101130_bib47","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.beha.2019.101130_bib48","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.101130_bib49","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2014","journal-title":"Leuk Res Rep"},{"issue":"1","key":"10.1016\/j.beha.2019.101130_bib50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/pbc.25694","article-title":"Atypical chronic myeloid leukemia in two pediatric patients","volume":"63","author":"Freedman","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2019.101130_bib51","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood-2019-127254","article-title":"Current treatments do not improve the prognosis of patients with atypical CML and unclassified MDS\/MPN. A joint report from Fi-LMC, FIM, Gfch and GFM","volume":"134","author":"Julien","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2019.101130_bib52","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ajh.25397","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: \"2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Patnaik","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2019.101130_bib53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.beha.2019.101130_bib54","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/blood-2018-10-879247","article-title":"Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia","volume":"133","author":"Piga","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101130_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122546","article-title":"A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2019.101130_bib56","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.101130_bib57","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1038\/bcj.2016.13","article-title":"Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis","volume":"6","author":"Tefferi","year":"2016","journal-title":"Blood Canc J"},{"issue":"2","key":"10.1016\/j.beha.2019.101130_bib58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2010-01-263087","article-title":"Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis","volume":"116","author":"Huls","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.101130_bib59","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/s41375-018-0228-4","article-title":"Blast-phase chronic myelomonocytic leukemia: more than just semantics","volume":"32","author":"Patnaik","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2019.101130_bib60","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2019.101130_bib61","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/1078-0432.CCR-07-1532","article-title":"Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome","volume":"14","author":"Kurzrock","year":"2008","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2019.101130_bib62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2125.2006.02615.x","article-title":"Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients","volume":"62","author":"Perez-Ruixo","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.beha.2019.101130_bib63","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1023\/B:DRUG.0000026254.97350.fe","article-title":"Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients","volume":"22","author":"Sparreboom","year":"2004","journal-title":"Investig New Drugs"},{"issue":"4","key":"10.1016\/j.beha.2019.101130_bib64","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.leu.2404539","article-title":"The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines","volume":"21","author":"Medeiros","year":"2007","journal-title":"Leukemia"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619301240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619301240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:17Z","timestamp":1761498437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619301240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1521692619301240"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.101130","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes \u2013 Advances in treatment","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.101130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101130"}}